Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping send shares in Europe’s most valuable listed company almost 5 per cent higher.
The Danish drugmaker reported a 26 per cent rise in net sales year on year to DKr290bn ($40bn) in 2024, beating expectations. The uptick was driven by demand for its obesity and diabetes drugs, particularly in the US.
Sales of obesity treatments rose 56 per cent to DKr65.1bn. Shares in the group rose 4.6 per cent in early morning trading.
您已阅读17%（513字），剩余83%（2593字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。